Asymmetric dimethylarginine (adma) in endocrine diseases
Eroğlu Altınova, Alev
MetadataShow full item record
Asymmetric dimethylarginine (ADMA) is the major inhibitor of nitric oxide biosynthesis in human. In recent reports, elevated plasma ADMA levels have been demonstrated to be associated with endothelial dysfunction and increased atherogenesis. Elevated ADMA levels, which contribute to the increased cardiovascular risk, have been determined in several endocrine diseases. The role of ADMA in various endocrine diseases such as diabetes mellitus, obesity and thyroid dysfunction will be discussed in this review.